Emer Cooke, EMA executive director (Photo by Tomas Tkacik / SOPA Images/Sipa USA)(Sipa via AP Images)

June 26, 2024 12:09 PM EDT

EMA calls for member states to lend a hand to ease GLP-1 supply bottlenecks

Anna Brown

News Reporter

The European Medicines Agency is calling for both pharma companies and its member states to address the supply pressures on GLP-1 weight loss and diabetes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EMA calls for member states to lend a hand to ease GLP-1 supply bottlenecks

Anna Brown

News Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

Biopharma leaders charting a path for the industry's LGBTQ+ community

GSK’s manufacturing sites in Singapore will use 100% renewable energy by 2025

EMA calls for mem­ber states to lend a hand to ease GLP-1 sup­ply bot­tle­necks

Anna Brown

News Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

Bio­phar­ma lead­ers chart­ing a path for the in­dus­try's LGBTQ+ com­mu­ni­ty

GSK’s man­u­fac­tur­ing sites in Sin­ga­pore will use 100% re­new­able en­er­gy by 2025

EMA calls for member states to lend a hand to ease GLP-1 supply bottlenecks

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Supreme Court narrowly rejects Purdue bankruptcy plan, says it gives Sacklers too much protection

Biopharma leaders charting a path for the industry's LGBTQ+ community

GSK’s manufacturing sites in Singapore will use 100% renewable energy by 2025